Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Zynerba Pharmaceuticals, Inc.:
We consent to the use of our report dated March 14, 2016 with respect to the consolidated balance sheets of Zynerba Pharmaceuticals, Inc. (formerly AllTranz, Inc.) as of December 31, 2015 and 2014, and the related consolidated statements of operations, redeemable convertible preferred stock, convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2015, incorporated herein by reference and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Philadelphia, PA
September 1, 2016